Novavax Inc. (NASDAQ:NVAX) was up 2% during trading on Friday . The company traded as high as $7.14 and last traded at $7.00, with a volume of 5,011,461 shares trading hands. The stock had previously closed at $6.86.

A number of equities research analysts have commented on NVAX shares. Vetr downgraded Novavax from a “buy” rating to a “hold” rating and set a $7.86 target price on the stock. in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Novavax in a research report on Thursday, June 2nd. Piper Jaffray Cos. restated an “overweight” rating and issued a $14.00 target price on shares of Novavax in a research report on Wednesday, June 29th. FBR & Co set a $17.00 target price on Novavax and gave the company a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research downgraded Novavax from a “hold” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Novavax currently has an average rating of “Buy” and a consensus target price of $11.05.

The company’s market capitalization is $1.91 billion. The company has a 50-day moving average of $7.33 and a 200-day moving average of $5.82.

Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.04. The company earned $2.50 million during the quarter, compared to analyst estimates of $8.03 million. The company’s revenue for the quarter was down 82.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.08) earnings per share. Equities analysts anticipate that Novavax Inc. will post ($1.07) earnings per share for the current fiscal year.

In related news, Director Gary C. Evans sold 50,000 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $5.41, for a total value of $270,500.00. Following the transaction, the director now directly owns 357,111 shares of the company’s stock, valued at approximately $1,931,970.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary C. Evans sold 18,998 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $6.50, for a total value of $123,487.00. Following the completion of the sale, the director now owns 321,979 shares of the company’s stock, valued at $2,092,863.50. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Novavax stock. Rhumbline Advisers increased its stake in shares of Novavax Inc. (NASDAQ:NVAX) by 12.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 271,881 shares of the biopharmaceutical company’s stock after buying an additional 30,395 shares during the period. Rhumbline Advisers owned approximately 0.10% of Novavax worth $2,281,000 as of its most recent filing with the SEC.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.